Navigation Links
Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal Infections Drug Market
Date:11/19/2008

However, Generic Erosion and a Dearth of Promising Emerging Therapies Will Result in Modest Annual Growth, According to a New Report from Decision Resources

WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to their improvements in safety and efficacy, physicians are increasingly prescribing next-generation antifungals such as Pfizer's Vfend, Schering-Plough's Noxafil, Merck's Cancidas, Astellas' Mycamine and Pfizer's Eraxis. Following the recent launches of several next-generation azoles (such as Vfend and Noxafil) and echinocandins (such as Cancidas, Mycamine and Eraxis), the severe fungal infections market has become increasingly competitive.

The new Pharmacor report entitled Severe Fungal Infections finds that market competition will continue to intensify and the generic erosion of key agents and a dearth of promising emerging therapies will limit growth to a modest two percent annually from 2007 to 2017 in the severe fungal infections drug market. The report also finds that no new products other than Basilea's isavuconazole are expected to generate significant sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan through 2017.

"Interviewed physicians regard isavuconazole as a highly promising new antifungal, and we forecast the agent to be an important driver in the severe fungal infection market through 2017," said Jose Avalos, Ph.D., analyst at Decision Resources. "Isavuconazole provides a favorable spectrum of activity and safety and is likely to be available as both an oral and intravenous therapy. This agent will compete with other marketed drugs in its class and its sales will help offset the declines due to patent expiries of key brands over the next 10 years."

About Severe Fungal Infections

In 2007, severe fungal infections treatments generated more than $1 billion in sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The market for severe fungal infections is highly complex due to the heterogeneous patient populations, risk groups, and pathogens involved. Although five major antifungal products have launched in recent years, the current pipeline remains sparse despite significant remaining unmet need.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources         Decision Resources, Inc.
    Christopher Comfort        Elizabeth Marshall
    781-296-2597               781-296-2563
    ccomfort@dresources.com    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016
2. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
3. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
4. Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008.
5. Satellite Healthcare Announces 2008 Norman S. Coplon Extramural Grants : Grants Foster Next-Generation Kidney Disease Researchers
6. Researchers find roadmap to next-generation cancer therapies
7. Fourth Annual Games for Health Conference Joins Health and Gaming Innovators to Discuss Next-Generation Game Technologies and Health Issues
8. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
9. iCAD Introduces Next-Generation TotalLook Film Digitizer
10. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
11. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017  According to the Centers for ... the end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the ... as mandated by certain health insurance regulations. ... The best time to get a flu shot is by the ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
Breaking Medicine Technology: